Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics.
Fuente:
PubMed
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Marine drugs
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1868266174400167937 |
|---|---|
| author | Zhang, Jinwei |
| author_facet | Zhang, Jinwei Zhang, Jinwei |
| collection | PubMed - marine biology |
| contents | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. Zhang, Jinwei Humans Aquatic Organisms Neoplasms Animals Metabolic Diseases Kidney Diseases Antineoplastic Agents Biological Products Structure-Activity Relationship Drug Development Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A-2), ilimaquinone, and Aplidin (plitidepsin). Key mechanisms include autophagy modulation, immune checkpoint inhibition, anti-inflammatory effects, and mitochondrial homeostasis. Novel findings reveal glycosides' dual role in cytotoxicity and immunomodulation, ilimaquinone's induction of the DNA damage response, and Aplidin's disruption of protein synthesis via eEF1A2 binding. Pharmacokinetic challenges and structure-activity relationships are critically analyzed, emphasizing nanodelivery systems and synthetic analog development. This review bridges mechanistic insights with translational potential, offering a cohesive framework for future drug development. |
| format | Artículo científico |
| id | pubmed_40710508 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Marine drugs |
| record_format | pubmed |
| spellingShingle | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. Zhang, Jinwei Humans Aquatic Organisms Neoplasms Animals Metabolic Diseases Kidney Diseases Antineoplastic Agents Biological Products Structure-Activity Relationship Drug Development Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. Zhang, Jinwei Humans Aquatic Organisms Neoplasms Animals Metabolic Diseases Kidney Diseases Antineoplastic Agents Biological Products Structure-Activity Relationship Drug Development Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A-2), ilimaquinone, and Aplidin (plitidepsin). Key mechanisms include autophagy modulation, immune checkpoint inhibition, anti-inflammatory effects, and mitochondrial homeostasis. Novel findings reveal glycosides' dual role in cytotoxicity and immunomodulation, ilimaquinone's induction of the DNA damage response, and Aplidin's disruption of protein synthesis via eEF1A2 binding. Pharmacokinetic challenges and structure-activity relationships are critically analyzed, emphasizing nanodelivery systems and synthetic analog development. This review bridges mechanistic insights with translational potential, offering a cohesive framework for future drug development. |
| title | Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. |
| topic | Humans Aquatic Organisms Neoplasms Animals Metabolic Diseases Kidney Diseases Antineoplastic Agents Biological Products Structure-Activity Relationship Drug Development |
| url | https://pubmed.ncbi.nlm.nih.gov/40710508/ |